In the PALOMA-3 trial, the subcutaneous formulation of amivantamab not only reduced infusion-related reactions but also unexpectedly showed a potential efficacy benefit over the IV version, including a statistically significant difference in overall survival. This suggests the route of administration may have biological implications.

The primary advantage of subcutaneous amivantamab extends beyond clinical safety to operational efficiency and patient well-being. It significantly reduces infusion time, freeing up limited oncology clinic resources and, more importantly, allowing patients with a limited life expectancy to spend less time in treatment and more with loved ones.

The Victoria 1 trial reported "historically low" discontinuation rates for the PI3K inhibitor alpelisib. This indicates that oncologists have become significantly better at proactively managing the drug's known toxicities, such as hyperglycemia. This real-world clinical maturation has improved the drug's tolerability and practical utility since its initial approval studies.

The Mariposa study showed an overall survival benefit for first-line amivantamab. However, since very few patients in the control arm received subsequent amivantamab, the benefit may simply demonstrate the drug's effectiveness at *any* point, not necessarily that it must be used first-line.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

The subcutaneous formulation is not just an alternative but should be considered the new standard of care for any patient eligible for amivantamab, regardless of the specific regimen. Its benefits are so significant that it may even expand the eligible patient pool to those previously hesitant due to long infusion times or reaction fears.

The discontinuation rate for pembrolizumab due to side effects was lower in the LITESPARK 022 trial compared to the earlier Keynote 564 trial (20%). This trend suggests that as clinicians gain more experience with immune checkpoint inhibitors, they are becoming more adept at managing immune-related adverse events, allowing more patients to complete their therapy.

While designed to prove non-inferiority, the PALOMA-3 trial unexpectedly suggested that the subcutaneous formulation might improve overall survival compared to the IV version. Although the study wasn't powered to confirm this finding and the reason is unclear, it serves as a powerful, reassuring point for clinicians discussing treatment options with patients.

Clinicians should avoid directly comparing the toxicity profiles of new ADCs, as the data often comes from different trial stages. A drug in a Phase 1 expansion cohort may appear more toxic than one with mature Phase 2 randomized data, making definitive safety assessments premature.